AP
Alnylam Pharmaceuticals Inc
🇺🇸XNAS.ALNYUnited StatesHealthcare
$240.86USDup +2.55 (+1.07%)OpenDelayed6:05 PM
Price$240.86+2.55 (+1.07%)
Profile
- Healthcare
- Biotechnology
- United States
Identity
- Exchange
- Nasdaq . XNAS
- Type
- Stock
- ISIN
- US02043Q1076
- CUSIP
- 02043Q107
Company
- Employees
- 2,500
- Headquarters
- Cambridge, United States
- Website
- https://www.alnylam.com
- CEO
- Dr. Yvonne L. Greenstreet M.B.A., M.D.
Market
- Shares outstanding
- 133.8M
- Market cap
- $32.23B
Key dates
- Next earnings
- Oct 29, 2026
Highlights
- Market cap
- $31.89B
- EPS LTM
- $5.84
- P/E LTM
- 51.14
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- $4.8B+95.14%up year on year
- Net income
- $807.99M+353.22%up year on year
- Gross margin
- 79.72%-4.69%down year on year
- Free cash flow
- $542.54M+1,141.59%up year on year
Other listings
These are the venues Finzer covers, not every venue that exists.
Business summary
No company summary reported yet.